Debiopharm, EORTC investigate triptorelin for treatment of salivary gland cancers

Debiopharm, EORTC investigate triptorelin for treatment of salivary gland cancers

Debiopharm International SA (Debiopharm), part of Debiopharm Group, a Swiss-based global biopharmaceutical company, today announced a collaboration in order to supply triptorelin pamoate 3.75 mg 1-month formulation for patients suffering from salivary gland cancer participating in a clinical study sponsored by the European Organisation for Research and Treatment of Cancer (EORTC).

The EORTC intergroup trial 1206:"A randomised phase II study to evaluate the efficacy and safety of chemotherapy vs (ADT) in patients with recurrent and/or metastatic, androgen receptor expressing, salivary " is coordinated by the EORTC Head and Neck Cancer Group in collaboration with the International Rare Cancer Initiative UK Salivary Gland Cancer Group. This study will accrue 152 patients at approximately 30 sites in 10 countries: Austria, Belgium, France, Germany, Greece, Hungary, Italy, the Netherlands, Portugal and the United Kingdom. The clinical study is expected to last until mid 2021.

Dr. Lisa Licitra of the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy, and Coordinator of this study says, "Androgen, estrogen and progesterone play a key role in the growth and development of several cancer types, e.g. breast, endometrium and prostate, and since the discovery of androgen receptors in salivary gland tumors, it is thought that androgen deprivation therapy might be beneficial for patients with expressing, salivary gland cancer. The EORTC 1206 intergroup trial will evaluate the efficacy and safety of therapy versus chemotherapy in patients with recurrent and/or metastatic, salivary gland cancer."

Salivary gland cancers are a rare and heterogeneous group of tumors. There is currently no standard of care for treating these cancers. The purpose of this study is to evaluate the efficacy and safety of chemotherapy versusandrogen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptors-expressing salivary gland cancers.

"Androgen deprivation therapy with triptorelin may slow progression of cancers expressing receptors", says Dr Eija Lundstrom, Medical Director at Debiopharm. "We are committed to support the clinical investigation of this promising treatment option of these rare cancers".


Explore further

Can RA-223 improve Enzalutamide efficacy for early castration resistant prostate cancer?

Provided by European Organisation for Research and Treatment of Cancer
Citation: Debiopharm, EORTC investigate triptorelin for treatment of salivary gland cancers (2016, January 14) retrieved 25 June 2019 from https://medicalxpress.com/news/2016-01-debiopharm-eortc-triptorelin-treatment-salivary.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more